A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED THREE-LOT CONSISITENCY STUDY IN HEALTHY ADULT VOLUNTEERS TO ASSESS IMMUNOGENICITY, AND CLINICAL ACCEPTABILITY OF A SINGLE-DOSE OF THE LIVE ORAL CHOLERA VACCINE CANDIDATE PXVX0200, VIBRIO CHOLERAE O1 SEROTYPE INABA VACCINE STRAIN CVD 103-HGR

Intervention/treatment:
CVD 103-HGR
Medical condition:
CHOLERA
Protocol code:
PXVX-VC-200-004
Control number:
175370
Status:
Closed
Approved:
July 11, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02094586
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 45 Years
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
David Cassie, Scientist, Clinical Research
Organization
Emergent BioSolutions Canada Inc.
Phone:
204-275-4589
Sponsor
PAXVAX CORPORATION

Results

See the results from the trial NCT02094586. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?